ZYN nicotine pouches are approved for adults 21 and older, with restrictions to safeguard public health and prevent youth use.
The Food and Drug Administration (FDA) authorized the marketing of 20 ZYN nicotine pouch products, the first approval of such products under the premarket tobacco product application (PMTA) pathway. The synthetic fiber pouches, designed for placement between the gum and lip, contain significantly lower levels of harmful constituents compared to cigarettes and most smokeless tobacco products.
The FDA’s evaluation concluded that the products pose a lower risk of cancer and other severe health conditions and may benefit adults transitioning from traditional tobacco. While youth use of nicotine pouches remains low, marketing restrictions are in place to prevent underage exposure.
“It’s critical that the manufacturer market these products responsibly to prevent youth use,” said Director Brian King of the FDA’s Center for Tobacco Products. “While current data show that youth use remains low, the FDA is closely monitoring the marketplace and is committed to taking action, as appropriate, to best protect public health.”
Despite the approval, the FDA emphasized that no tobacco product is entirely safe and warned against initiation by non-users. The authorization applies only to specific flavors and nicotine strengths and does not allow claims of reduced health risks.
As the Lord Leads, Pray with Us…
- For Director King to receive God’s wisdom as he heads the FDA Center for Tobacco Products.
- For Robert F. Kennedy, Jr. as he prepares for the Senate confirmation process to head the Department of Health and Human Services.
- For members of the Senate as they consider the nomination of Marty Makary for FDA commissioner.
Sources: Food and Drug Administration
